Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.

Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, Hamdy FC, Gillatt D, Holly J, Macefield R, Moody H, Neal DE, Walsh E, Martin RM, Metcalfe C.

Cancer Prev Res (Phila). 2018 Oct 11. doi: 10.1158/1940-6207.CAPR-18-0147. [Epub ahead of print]

PMID:
30309839
2.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2018 Sep 20. doi: 10.1038/s41388-018-0501-z. [Epub ahead of print]

PMID:
30237440
3.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

4.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11.

PMID:
29892016
5.

AA9int: SNP Interaction Pattern Search Using Non-Hierarchical Additive Model Set.

Lin HY, Huang PY, Chen DT, Tung HY, Sellers TA, Pow-Sang J, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Neal DE, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ; PRACTICAL consortium, Park JY.

Bioinformatics. 2018 Jun 7. doi: 10.1093/bioinformatics/bty461. [Epub ahead of print]

PMID:
29878078
6.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

7.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

PMID:
29662167
8.

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, Sterne JAC, Holding P, Ben-Shlomo Y, Brindle P, Williams NJ, Hill EM, Ng SY, Toole J, Tazewell MK, Hughes LJ, Davies CF, Thorn JC, Down E, Davey Smith G, Neal DE, Hamdy FC; CAP Trial Group.

JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.

9.

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer.

Gilbert R, Tilling K, Martin RM, Lane JA, Davis M, Hamdy FC, Neal DE, Donovan JL, Metcalfe C.

Cancer Causes Control. 2018 Mar;29(3):383-388. doi: 10.1007/s10552-018-1014-3. Epub 2018 Feb 16.

10.

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; PRACTICAL consortium, Easton D, Eeles RA, Muir K.

Br J Cancer. 2018 Mar 20;118(6):e16. doi: 10.1038/bjc.2018.6. Epub 2018 Feb 13.

11.

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE.

EMBO Mol Med. 2018 Mar;10(3). pii: e8274. doi: 10.15252/emmm.201708274.

12.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.

13.

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.

Donovan JL, Young GJ, Walsh EI, Metcalfe C, Lane JA, Martin RM, Tazewell MK, Davis M, Peters TJ, Turner EL, Mills N, Khazragui H, Khera TK, Neal DE, Hamdy FC; ProtecT Study Group.

J Clin Epidemiol. 2018 Apr;96:35-46. doi: 10.1016/j.jclinepi.2017.12.019. Epub 2017 Dec 27.

14.

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.

Young GJ, Harrison S, Turner EL, Walsh EI, Oliver SE, Ben-Shlomo Y, Evans S, Lane JA, Neal DE, Hamdy FC, Donovan JL, Martin RM, Metcalfe C.

BMJ Open. 2017 Oct 30;7(10):e017729. doi: 10.1136/bmjopen-2017-017729.

15.

Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.

Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Nicol D, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ; CRUK-ICGC Prostate Group, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS.

PLoS Genet. 2017 Sep 25;13(9):e1007001. doi: 10.1371/journal.pgen.1007001. eCollection 2017 Sep.

16.

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; PRACTICAL consortium, Easton D, Eeles RA, Muir K.

Br J Cancer. 2017 Aug 22;117(5):734-743. doi: 10.1038/bjc.2017.231. Epub 2017 Aug 1. Erratum in: Br J Cancer. 2018 Feb 13;:.

17.

DESNT: A Poor Prognosis Category of Human Prostate Cancer.

Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY; CancerMap Group, Eeles R, Lynch AG, Ross-Adams H, Lamb AD, Neal DE, Sethia K, Mills RD, Ball RY, Curley H, Clark J, Moulton V, Cooper CS.

Eur Urol Focus. 2017 Mar 6. pii: S2405-4569(17)30025-1. doi: 10.1016/j.euf.2017.01.016. [Epub ahead of print]

18.

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.

Er V, Biernacka K, Simpkin AJ, Martin RM, Jeffreys M, Emmett P, Gilbert R, Avery KNL, Walsh E, Davis M, Donovan JL, Neal DE, Hamdy FC, Holly JMP, Lane JA.

Cancer Causes Control. 2017 Aug;28(8):877-888. doi: 10.1007/s10552-017-0910-2. Epub 2017 Jun 23.

19.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

20.

Asporin is a stromally expressed marker associated with prostate cancer progression.

Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA.

Br J Cancer. 2017 Mar 14;116(6):775-784. doi: 10.1038/bjc.2017.15. Epub 2017 Feb 2.

21.

10-Year Outcomes in Localized Prostate Cancer.

Hamdy FC, Donovan JL, Neal DE.

N Engl J Med. 2017 Jan 12;376(2):180. doi: 10.1056/NEJMc1614342. No abstract available.

22.

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ.

Int J Cancer. 2017 Apr 15;140(8):1881-1887. doi: 10.1002/ijc.30604. Epub 2017 Jan 30.

23.

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?

Harrison S, Tilling K, Turner EL, Lane JA, Simpkin A, Davis M, Donovan J, Hamdy FC, Neal DE, Martin RM.

Cancer Causes Control. 2016 Dec;27(12):1465-1474. Epub 2016 Nov 9.

24.

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC.

Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1.

PMID:
27815082
25.

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, Stearn S, Warren AY, Lamb AD, Shaw G, Sharma N, Thomas BC, Tran MG, Neal DE, Shah NC.

BJU Int. 2016 Nov;118(5):779-784. doi: 10.1111/bju.13513. Epub 2016 May 24.

26.

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.

Walsh EI, Turner EL, Lane JA, Donovan JL, Neal DE, Hamdy FC, Martin RM; the CAP & ProtecT Trial Groups; Investigators; Research staff; Management Committee; CAP & ProtecT Trial Steering Committee; Data Monitoring Committee; Administrative staff.

Trials. 2016 Oct 13;17(1):497.

27.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

28.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

29.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.

30.

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, Bucklow LJ, Luxton HJ, Johnston T, Massie CE, Pugh M, Warren AY, Barker P, Burling K, Lynch AG, George A, Burge J, Corcoran M, Stearn S, Lamb AD, Sharma NL, Shaw GL, Neal DE, Whitaker HC.

Endocr Relat Cancer. 2016 Oct;23(10):797-812. doi: 10.1530/ERC-16-0287. Epub 2016 Aug 30.

PMID:
27578825
31.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network; PRACTICAL consortium, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D.

Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.

32.

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Madhu B, Shaw GL, Warren AY, Neal DE, Griffiths JR.

Metabolomics. 2016;12:120. Epub 2016 Jun 30.

33.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

34.

Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer.

Asim M, Massie CE, Neal DE.

Mol Cell Oncol. 2016 Feb 24;3(3):e1140262. doi: 10.1080/23723556.2016.1140262. eCollection 2016 May.

35.

Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Davies CF, Ng SY, Neal DE, Hamdy FC, Albertsen P, Reid CM, Oxley J, McFarlane J, Robinson MC, Adolfsson J, Zietman A, Baum M, Koupparis A, Martin RM.

Br J Cancer. 2016 Jun 28;115(1):90-4. doi: 10.1038/bjc.2016.162. Epub 2016 Jun 2.

36.

Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.

Bonilla C, Lewis SJ, Rowlands MA, Gaunt TR, Davey Smith G, Gunnell D, Palmer T, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Martin RM, Holly JM.

Int J Cancer. 2016 Oct 1;139(7):1520-33. doi: 10.1002/ijc.30206. Epub 2016 Jun 23.

37.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

38.

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Thorn JC, Turner EL, Hounsome L, Walsh E, Down L, Verne J, Donovan JL, Neal DE, Hamdy FC, Martin RM, Noble SM; CAP trial group.

BMJ Open. 2016 Apr 29;6(4):e011063. doi: 10.1136/bmjopen-2016-011063.

39.

Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.

Price AJ, Travis RC, Appleby PN, Albanes D, Barricarte Gurrea A, Bjørge T, Bueno-de-Mesquita HB, Chen C, Donovan J, Gislefoss R, Goodman G, Gunter M, Hamdy FC, Johansson M, King IB, Kühn T, Männistö S, Martin RM, Meyer K, Neal DE, Neuhouser ML, Nygård O, Stattin P, Tell GS, Trichopoulou A, Tumino R, Ueland PM, Ulvik A, de Vogel S, Vollset SE, Weinstein SJ, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers, and Prostate Cancer Collaborative Group.

Eur Urol. 2016 Dec;70(6):941-951. doi: 10.1016/j.eururo.2016.03.029. Epub 2016 Apr 6.

40.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A; PRACTICAL consortium, Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B.

Nat Commun. 2016 Apr 7;7:10979. doi: 10.1038/ncomms10979.

41.

Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.

Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, Lathrop M, Davey Smith G; PRACTICAL consortium.

BMC Med. 2016 Apr 4;14:66. doi: 10.1186/s12916-016-0602-x.

42.

Gene regulatory mechanisms underpinning prostate cancer susceptibility.

Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, Grönberg H, Lindberg J, Wei GH, Wiklund F.

Nat Genet. 2016 Apr;48(4):387-97. doi: 10.1038/ng.3523. Epub 2016 Mar 7.

PMID:
26950096
43.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JAMJL, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak M, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE.

Cancer Res. 2016 Apr 15;76(8):2288-2300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

44.

A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.

Marzec J, Mao X, Li M, Wang M, Feng N, Gou X, Wang G, Sun Z, Xu J, Xu H, Zhang X, Zhao SC, Ren G, Yu Y, Wu Y, Wu J, Xue Y, Zhou B, Zhang Y, Xu X, Li J, He W, Benlloch S, Ross-Adams H, Chen L, Li J, Hong Y, Kote-Jarai Z, Cui X, Hou J, Guo J, Xu L, Yin C, Zhou Y, Neal DE, Oliver T, Cao G, Zhang Z, Easton DF, Chelala C; PRACTICAL Consortium; CHIPGECS Group, Al Olama AA, Eeles RA, Zhang H, Lu YJ.

Oncotarget. 2016 Apr 19;7(16):21393-403. doi: 10.18632/oncotarget.7250.

45.

Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts.

Simpkin AJ, Donovan JL, Tilling K, Athene Lane J, Martin RM, Albertsen PC, Bill-Axelson A, Ballentine Carter H, Bosch JL, Ferrucci L, Hamdy FC, Holmberg L, Jeffrey Metter E, Neal DE, Parker CC, Metcalfe C.

BJU Int. 2016 Dec;118(6):911-918. doi: 10.1111/bju.13422. Epub 2016 Feb 29.

46.

Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer.

Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, Cooper PR, Donovan JL, Hamdy FC, Jinga V, Okamoto I, Jonasson JG, Tryggvadottir L, Johannsdottir H, Kristinsdottir AM, Masson G, Magnusson OT, Iordache PD, Helgason A, Helgason H, Sulem P, Gudbjartsson DF, Kong A, Jonsson E, Barkardottir RB, Einarsson GV, Rafnar T, Thorsteinsdottir U, Mates IN, Neal DE, Catalona WJ, Mayordomo JI, Kiemeney LA, Thorleifsson G, Stefansson K.

Hum Mol Genet. 2016 Mar 1;25(5):1008-18. doi: 10.1093/hmg/ddv622. Epub 2016 Jan 5.

47.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

48.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

49.

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, Giles GG, Giovannucci E, Goodman GE, Goodman PJ, Gunter MJ, Hamdy FC, Heliövaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Hoffman-Bolton J, Hoover RN, Johansson M, Khaw KT, King IB, Knekt P, Kolonel LN, Le Marchand L, Männistö S, Martin RM, Meyer HE, Mondul AM, Moy KA, Neal DE, Neuhouser ML, Palli D, Platz EA, Pouchieu C, Rissanen H, Schenk JM, Severi G, Stampfer MJ, Tjønneland A, Touvier M, Trichopoulou A, Weinstein SJ, Ziegler RG, Zhou CK, Allen NE; Endogenous Hormones Nutritional Biomarkers Prostate Cancer Collaborative Group.

Am J Clin Nutr. 2015 Nov;102(5):1142-57. doi: 10.3945/ajcn.115.114306. Epub 2015 Oct 7.

50.

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.

Gilbert R, Martin RM, Evans DM, Tilling K, Davey Smith G, Kemp JP, Lane JA, Hamdy FC, Neal DE, Donovan JL, Metcalfe C.

PLoS One. 2015 Oct 2;10(10):e0136735. doi: 10.1371/journal.pone.0136735. eCollection 2015.

Supplemental Content

Loading ...
Support Center